105746-46-1 Usage
Description
N-(TRANS-4-TERT-BUTYL-CYCLOHEXYL)CARBONYL-D-PHENYLALANINE, also known as an analogue of N-(Cyclohexylcarbonyl)-D-phenylalanine, is a chemical compound with specific structural features that contribute to its functionality in various applications. It is characterized by its unique arrangement of atoms and molecular structure, which allows it to interact with biological systems in a targeted manner.
Uses
Used in Pharmaceutical Industry:
N-(TRANS-4-TERT-BUTYL-CYCLOHEXYL)CARBONYL-D-PHENYLALANINE is used as an oral hypoglycemic agent for the treatment of diabetes. As an analogue of N-(Cyclohexylcarbonyl)-D-phenylalanine, it helps in regulating blood sugar levels, providing a potential therapeutic option for patients with diabetes. Its chemical structure allows it to effectively target and modulate the relevant biological pathways involved in glucose metabolism, thus contributing to its hypoglycemic effects.
Check Digit Verification of cas no
The CAS Registry Mumber 105746-46-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,7,4 and 6 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 105746-46:
(8*1)+(7*0)+(6*5)+(5*7)+(4*4)+(3*6)+(2*4)+(1*6)=121
121 % 10 = 1
So 105746-46-1 is a valid CAS Registry Number.
105746-46-1Relevant articles and documents
N-(Cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2
Shinkai,Nishikawa,Sato,Toi,Kumashiro,Seto,Fukama,Dan,Toyoshoma
, p. 1436 - 1441 (2007/10/02)
A series of analogues of N-(cyclohexylcarbonyl)-D-phenylalanine (5) have been synthesized and evaluated for their hypoglycemic activity. Relationships were studied between the activity and the three-dimensional structure of the acyl moiety, which was characterized by high-resolution 1H NMR spectroscopy and MNDO calculations. The role of the carboxyl group of the phenylalanine moiety was also studied by comparing the activities of the enantiomers, the decarboxyl derivative, the esters, and the amides of the phenylalanine derivatives. Thus, the structural requirements for possessing hypoglycemic activity was elucidated and a highly active compound, N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine (13) was obtained, which showed a 20% blood glucose decrease at an oral dose of 1.6 mg/kg in fasted normal mice.